Oncology

Session # 1524

Expanding BRCA1/2 testing criteria to include other confirmed breast and ovarian cancer susceptibility genes

  • Breast cancer susceptibility gene mutations are detected in 8.6% of breast cancer patients undergoing multigene panel testing who meet BRCA1/2 testing criteria (3.4% in BRCA1/2 and 5.2% in other genes).
  • Ovarian cancer susceptibility gene mutations are detected in 13.0% of OC patients undergoing multigene panel testing (8.0% for BRCA1/2 and 5.0% in other genes).
  • Inclusion of additional risk genes increases detection rate for BC and OC patients meeting BRCA1/2 testing criteria by 152.9% and 62.5%, respectively

  • Authors: Fergus J. Couch; Hermela Shimelis; Jill Dolinsky; Eric C. Polley; Carrie Horton; Amal Yussuf; Lily Hoang; Jenna Lilyquist; Virginia Speare; Chunling Hu; Steven N. Hart; Holly LaDuca
  • Collaborators: Mayo Clinic
  • Conference: American Society of Clinical Oncology (ASCO) 2018
  • Date: Saturday, Jun 02, 2018 1:15pm - 4:45pm

Search Results

Start your search...